Literature DB >> 28454987

Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Jean-Michel Lavoie1, Samir Bidnur2, Peter C Black2, Bernhard J Eigl1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28454987     DOI： 10.1016/j.urology.2017.04.001

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  3 in total

Review 1.  The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.

Authors:  Yaoan Wen; Yeda Chen; Xiaolu Duan; Wei Zhu; Chao Cai; Tuo Deng; Guohua Zeng
Journal:  Clin Exp Med       Date:  2019-08-12       Impact factor: 3.984

2.  Immunological perspective on the malignant progression of renal clear cell carcinoma.

Authors:  Ji Liu; Wentao Zhang; Kang Lin; Wenchao Ma; Wei Li; Xudong Yao
Journal:  Ann Transl Med       Date:  2021-10

Review 3.  A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.

Authors:  Fu-Shun Hsu; Chun-Hung Su; Kou-How Huang
Journal:  J Immunol Res       Date:  2017-12-10       Impact factor: 4.818
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.